Recent Updates
Recently added Catalysts

OP-3136

Phase 1

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Small Molecules | Oncology |Olema Oncology, Inc.|Trials Updated: Oct 5, 2026

OP-3136 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jan 2025

OP-3136 target and mechanism

Molecular targetKAT6
Target classLysine Acetyltransferase
ModalitySmall Molecules

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment180

FDA Designations

No designations recorded

OP-3136 clinical trials

OP-3136 · 1 trial · 6 indications

Phase 1 1
NCT06784193Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsAdvanced or Metastatic ER+ HER2- Breast Cancer (mBC)
RECRUITING180 Analytics
PHASE1RECRUITING
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with dose-limiting toxicities in the Dose Escalation Arms
Up to 28 days
Incidence of adverse events and laboratory abnormalities
Up to 26 months

Secondary Endpoints

Maximum observed concentration (Cmax)
Up to 26 months
Time to maximum concentration (Tmax)
Up to 26 months
Area under the curve from time zero to 24 hours (AUC0-24)
Up to 26 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1A Dose Escalation monotherapyEXPERIMENTAL -
Part 1B Dose Escalation in combination with fulvestrantEXPERIMENTAL -
Part 1C Dose Escalation in combination with palazestrantEXPERIMENTAL -
Part 2A Dose Expansion monotherapy - mBCEXPERIMENTAL -
Part 2A Dose Expansion monotherapy - mCRPCEXPERIMENTAL -
Part 2B Dose Expansion in combination with fulvestrant OR palazestrant-mBC @ RDE 1EXPERIMENTAL -
Part 2B Dose Expansion in combination with fulvestrant OR palazestrant-mBC @ RDE 2EXPERIMENTAL -

Interventions

NameTypeDescription
OP-3136DRUGSelective inhibitor of HAT enzymes KAT6A and KAT6B
FulvestrantDRUGSelective estrogen receptor degrader (SERD)
PalazestrantDRUGComplete estrogen receptor antagonist (CERAN)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites25

Key Inclusion Criteria: * Participants with advanced or metastatic ER+HER2- breast cancer, mCRPC, or NSCLC (Part 1) or advanced or metastatic ER+HER2- BC or mCRPC (Part 2). * Part 1A (Dose escalation for OP-3136 monotherapy): Participants must have a tumor that is unresectable or metastatic and for...

Countries:United StatesAustraliaFranceHong KongIrelandSpain
Unlock Eligibility Criteria

Competitive Landscape -Breast Cancer 601 trials (matched to "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)")

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWOct 5, 2026NCT06784193lastUpdatePostDate: changed
LOWOct 5, 2026NCT06784193lastUpdatePostDate: changed

Frequently asked questions about OP-3136

What is OP-3136?

OP-3136 is an investigational small molecule developed by Olema Oncology for advanced or metastatic ER+ HER2- breast cancer. It is also being studied in advanced or metastatic non-small cell lung cancer and castration-resistant prostate cancer. It is in Phase 1 clinical development and has not been approved by the FDA.

What does OP-3136 target?

OP-3136 targets KAT6, a lysine acetyltransferase enzyme. By acting on this target, OP-3136 is designed as a small molecule therapeutic being evaluated in biomarker-selected patients with advanced or metastatic solid tumors, including ER+ HER2- breast cancer.

Who is developing OP-3136?

OP-3136 is being developed by Olema Oncology, Inc., which trades on Nasdaq under the ticker OLMA. The company is running the Phase 1 program for the asset in advanced or metastatic solid tumors, including ER+ HER2- breast cancer.

What phase is OP-3136 in?

OP-3136 is in Phase 1 clinical development. It is investigational and is being studied in a single recruiting Phase 1 trial in advanced or metastatic solid tumors, including ER+ HER2- breast cancer, NSCLC, and mCRPC.

What clinical trials is OP-3136 in?

OP-3136 is being studied in the Phase 1 trial NCT06784193, titled Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors. The trial is recruiting, is controlled and randomized, and plans to enroll 180 participants across the United States, Australia, France, Hong Kong, Ireland, and Spain.

What is OP-3136 used for in breast cancer?

OP-3136 is being evaluated for advanced or metastatic ER+ HER2- breast cancer. The Phase 1 trial NCT06784193 also enrolls patients with metastatic breast cancer and lists fulvestrant and palazestrant among its conditions, and it is a biomarker-selected study in adults 18 years and older.